.Pharmacolibrary.Drugs.C_CardiovascularSystem.C03X_OtherDiuretics.C03XA01_Tolvaptan.Tolvaptan

Information

Tolvaptan is a selective vasopressin V2-receptor antagonist used for the treatment of hyponatremia (low sodium levels in the blood) due to syndrome of inappropriate antidiuretic hormone secretion (SIADH), heart failure, and autosomal dominant polycystic kidney disease (ADPKD). It is an approved oral medication.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.

References

1. Van Wart, SA, et al., & Mager, DE (2013). Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharmaceutics & drug disposition 34(6) 336–347. DOI:10.1002/bdd.1849 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23794414

2. Van Wart, SA, et al., & Mager, DE (2013). Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharmaceutics & drug disposition 34(9) 527–539. DOI:10.1002/bdd.1863 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24123104

3. Yi, S, et al., & Yu, KS (2012). Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men. Journal of cardiovascular pharmacology 59(4) 315–322. DOI:10.1097/FJC.0b013e318241e89c PUBMED:https://pubmed.ncbi.nlm.nih.gov/22130104

Revisions

• 06/2025 initial generated model